Investors May Have Lukewarm Reception to CSL's Earnings, Restructure -- Market Talk

Dow Jones

Aug 19

2346 GMT - RBC Capital Markets analyst Craig Wong-Pan thinks CSL's stock may dip today after the company announced its annual earnings and a sweeping restructuring, which includes spinning off its flu-vaccine unit Seqirus. Wong-Pan says CSL's main blood-products unit Behring missed on revenue and gross profit, that FY 2026 guidance was lower than expected, and the planned restructuring creates somewhat of a messy result. In its stock-market release, CSL painted a rosier picture, saying underlying FY 2025 profit rose 14% at constant currency and that the result was on target. As of Monday's close, CSL's stock had retreated some 3.6% so far this year. (mike.cherney@wsj.com)

(END) Dow Jones Newswires

August 18, 2025 19:46 ET (23:46 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2560134682"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560134682\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560134682?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 07:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560134682","market":"sh","top_or_hot":-1,"title":"Investors May Have Lukewarm Reception to CSL's Earnings, Restructure -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2346 GMT - RBC Capital Markets analyst Craig Wong-Pan thinks CSL's stock may dip today after the company announced its annual earnings and a sweeping restructuring, which includes spinning off its flu-vaccine unit Seqirus. Wong-Pan says CSL's main blood-products unit Behring missed on revenue and gross profit, that FY 2026 guidance was lower than expected, and the planned restructuring creates somewhat of a messy result. In its stock-market release, CSL painted a rosier picture, saying underlying FY 2025 profit rose 14% at constant currency and that the result was on target. As of Monday's close, CSL's stock had retreated some 3.6% so far this year. (mike.cherney@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 18, 2025 19:46 ET (23:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Investors May Have Lukewarm Reception to CSL's Earnings, Restructure -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvestors May Have Lukewarm Reception to CSL's Earnings, Restructure -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-19 07:46</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2346 GMT - RBC Capital Markets analyst Craig Wong-Pan thinks CSL's stock may dip today after the company announced its annual earnings and a sweeping restructuring, which includes spinning off its flu-vaccine unit Seqirus. Wong-Pan says CSL's main blood-products unit Behring missed on revenue and gross profit, that FY 2026 guidance was lower than expected, and the planned restructuring creates somewhat of a messy result. In its stock-market release, CSL painted a rosier picture, saying underlying FY 2025 profit rose 14% at constant currency and that the result was on target. As of Monday's close, CSL's stock had retreated some 3.6% so far this year. (mike.cherney@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 18, 2025 19:46 ET (23:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSL.AU","symbol_name":"CSL LIMITED","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2560134682","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560134682","pubTimestamp":1755560760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2346 GMT - RBC Capital Markets analyst Craig Wong-Pan thinks CSL's stock may dip today after the company announced its annual earnings and a sweeping restructuring, which includes spinning off its flu-vaccine unit Seqirus. Wong-Pan says CSL's main blood-products unit Behring missed on revenue and gross profit, that FY 2026 guidance was lower than expected, and the planned restructuring creates somewhat of a messy result. In its stock-market release, CSL painted a rosier picture, saying underlying FY 2025 profit rose 14% at constant currency and that the result was on target. As of Monday's close, CSL's stock had retreated some 3.6% so far this year. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CSL.AU":"CSL LIMITED","CSL":"卡莱尔伙伴","ISBC":"投资者银行"},"translate_title":"投资者可能对CSL的盈利和重组反应冷淡——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1,"CSL.AU":0.9,"CSL":1},"content_text":"2346 GMT - RBC Capital Markets analyst Craig Wong-Pan thinks CSL's stock may dip today after the company announced its annual earnings and a sweeping restructuring, which includes spinning off its flu-vaccine unit Seqirus. Wong-Pan says CSL's main blood-products unit Behring missed on revenue and gross profit, that FY 2026 guidance was lower than expected, and the planned restructuring creates somewhat of a messy result. In its stock-market release, CSL painted a rosier picture, saying underlying FY 2025 profit rose 14% at constant currency and that the result was on target. As of Monday's close, CSL's stock had retreated some 3.6% so far this year. (mike.cherney@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 18, 2025 19:46 ET (23:46 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}